# Vaccine targeting HIV sites of vulnerability

> **NIH VA I01** · JAMES J PETERS VA  MEDICAL CENTER · 2022 · —

## Abstract

Project Summary/Abstract
 Effective HIV vaccines are not yet available. Of the phase 2b/3 vaccine trials, only the Thai RV144 trial
showed efficacy (31%, p=0.04), and high levels of antibodies (Abs) against the V1V2 domain of HIV envelope
(Env) were found to be the only primary immune correlate of reduced virus acquisition. Studies of vaccines in
SIV or SHIV-challenged monkeys have since recapitulated these findings. To improve upon the RV144 vaccine,
we have designed V1V2-targeted vaccine candidates and identified the most immunogenic: V1V2/A244-2J9C,
a protein with V1V2 of CRF_01.AE strain A244 spliced into a bacterial trimeric protein scaffold, 2J9C. With our
unique vaccine strategy centered on targeting V1V2 using novel recombinant subunit immunogens, we have
demonstrated the capacity to induce an Ab response in plasma and vaginal secretion that was focused on V1V2
and diverted from other more immunodominant sites on Env. The elicited Abs displayed cross-reactivity with
strains from multiple clades, durability of 1-2 years after the last boost, and antiviral functions including Ab-
dependent cellular phagocytosis (ADCP), Ab-dependent cellular cytotoxicity (ADCC), and complement
activation—activities that are not readily achieved by immunization with intact gp120. V1V2/A244-2J9C DNA has
also been shown as an effective prime, focusing the Ab response on the specific V2 region that accounted for
reduced infection in RV144. Altogether these data provide evidence supporting the validation of our lead vaccine
candidate and vaccination approach. A US patent has been issued for our V1V2-scaffold designs, with the VA
as one of the assignees.
 This application proposes to produce the lead immunogen V1V2/A244-2J9C under cGMP (current Good
Manufacturing Practice) as both DNA plasmid and protein, and test its optimized delivery in order to pave the
way toward a human phase I clinical trial. To accomplish this goal, four specific aims are proposed. Aim 1 is to
generate a master bank of E. coli transformed with the V1V2/A244-2J9C-expressing DNA plasmid. In Aim 2 we
will test the cGMP-grade V1V2/A244-2J9C-encoding DNA for protein production in transiently transfected 293T
cells and for immunogenicity in rabbits. In vitro protein analysis will include expression efficiency, mass,
oligomerization, glycosylation, stability, and reactivity with a panel of monoclonals Abs (mAbs). Aim 3 is to
produce a master bank of HEK293T GnTi-/- cells and a pilot batch of V1V2/A244-2J9C protein using the plasmid
from Aim 1. Finally, Aim 4 will test purification methods and conduct in vitro analysis for V1V2/A244-2J9C protein
from Aim 3 and then perform in vivo rabbit immunogenicity testing with V1V2/A244-2J9C DNA and protein.
 The cGMP production will be done by Waisman BioManufacturing, associated with the University of
Wisconsin-Madison, under the supervision of Drs. Carl A. Ross and Brian M. Dattilo. In vitro immunogen analysis,
protein purification, rabbit vaccination, and...

## Key facts

- **NIH application ID:** 10248003
- **Project number:** 1I01BX005616-01
- **Recipient organization:** JAMES J PETERS VA  MEDICAL CENTER
- **Principal Investigator:** Catarina E Hioe
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2022
- **Award amount:** —
- **Award type:** 1
- **Project period:** 2021-10-01 → 2025-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10248003

## Citation

> US National Institutes of Health, RePORTER application 10248003, Vaccine targeting HIV sites of vulnerability (1I01BX005616-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10248003. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*